About
Terremoto is a clinical-stage company breaking new ground in the targeted therapy landscape in oncology and genetic disease.
Terremoto is a clinical-stage company breaking new ground in the targeted therapy landscape in oncology and genetic disease.
We develop groundbreaking, best-in-class precision therapies to meet urgent patient needs. Through relentless science and deep purpose, we bring life-changing hope to those who need it most.
At Terremoto, we are breaking open the covalent drug universe with the power of lysine-targeted chemistry. In harnessing lysine-based covalency across the disease spectrum, we are focused on developing both best-in-class therapies against known drug targets and first-in-class medicines against the previously undruggable. Our founders helped create this emergent area of science, enabling our team of world-class chemists, biologists and drug developers to pursue a well-defined platform approach and translate treatments to patients as quickly as possible.
We view ourselves as champions for patients. The ultimate driving force behind our work is bringing highly effective medicines to people with devastating diseases as quickly as we possibly can.
With a leadership team and advisory board bringing hundreds of collective years of experience in drug discovery, development, and global regulatory approval, we have the expertise to turn our ambitious vision into life-changing therapies.





















































